GLOBAL ACTION TO DRIVE INNOVATION IN ALZHEIMER’S DISEASE AND OTHER DEMENTIAS: CONNECTING RESEARCH, REGULATION AND ACCESS

DECEMBER 15-16, 2015
LAUSANNE, SWITZERLAND
ABOUT THE WORKSHOP

The workshop will provide an international forum for stakeholders to articulate achievements and opportunities in biomedical research and health innovation for Alzheimer’s disease and other dementias – aiming to address the challenges and barriers to the introduction into the market of effective treatments and diagnostics. Following on last year’s conference, this year’s will feature developments in regulatory and access pathways for potential innovations in dementia and the perspectives of regulators and payers, specifically the evidence and tools needed to support regulatory and payer evaluation of innovations. Stakeholders will discuss approaches to encourage more innovative research, shared governance, and health economic models.

Through an exchange to encourage innovation, representatives from governments, regulatory agencies, the research community, patient organisations, industry and insurers will discuss progress and future action in:

• The current therapeutic pipeline and progress on the path to 2025, including advancing patient focused drug development and implementing outcomes-based approaches in treatment;

• Implementing innovative biomedical research tools in product development and regulatory models, including the scope for adaptive regulatory processes, enhanced clinical trial designs and a strengthened diagnostic environment;

• The current state of biomarker evidence and research, and the required advances needed for regulatory use;

• Access to future therapies and diagnostics, including the evidence and tools needed by payers to ensure sustainability.

This workshop is a follow-up event to the OECD workshop on “Enhancing Translational Research and Clinical Development in Alzheimer’s Disease and Other Dementia: The Way Forward” in Lausanne, Switzerland in November 2014 supported by the Swiss Government, The Global CEO Initiative on Alzheimer’s Disease (CEOi) and Alzheimer’s Disease International (ADI). It is intended to provide input to ongoing international policy discussions on Alzheimer’s and dementia, including the work of the World Dementia Council, G7, OECD, WHO and others. More information on the OECD’s work on dementia is available here: http://www.oecd.org/health/dementia.htm

#ADLausanne

www.oecd.org/sti/biotech/alzheimers-dementia-research-workshop.htm
# PROGRAM AGENDA

## DAY ONE - 15 DECEMBER

**Workshop Moderator/ Emcee**  
Isabella Beretta, *Federal Department of Economic Affairs, Education and Research, Swiss State Secretariat for Education, Research and Innovation*

## OPENING AND WELCOME  
9:00 - 10:00

Tania Dussey-Cavassini, *Vice-Director General of Swiss Federal Office of Public Health, Ambassador for Global Health, Switzerland*  
Peter Schintlmeister, *Chair, Working Party on Biotechnology, Nanotechnology and Converging Technologies, Organisation for Economic Co-operation and Development*  
Marc Wortmann, *Executive Director, Alzheimer’s Disease International*  
George Vradenburg, *Convener, The Global CEO Initiative on Alzheimer’s Disease, Member, World Dementia Council*

## SESSION 1 - FACILITATING DRUG DEVELOPMENT  
10:00 - 13:00

Moderated by George Vradenburg, *Convener, The Global CEO Initiative on Alzheimer’s, United States*

The past decade of research has failed to produce any new therapies to address the huge unmet needs of dementia prevention, treatment and care. Yet, we are possibly on the cusp of a wave of innovation as several rigorous research programs are nearing the conclusion of successful testing, raising hopes that innovative new approaches will finally reach persons with or at risk for dementia.

The need to optimize the navigational path for assessing these interventions and their access to the market requires an understanding of the drug pipeline, the evidence needed by regulatory and payer authorities to review prospective interventions and the short, medium, and long-term strategies and associated stakeholder actions to deliver successful interventions to those with or at risk of dementia. The purpose of this session is to define what innovations are in development and what is needed to ensure these innovations reach the market.

Andrea Pfeifer, *CEO, AC Immune*

1.B: *Innovation in Prevention Therapies*  
Tobias Hartmann, *Professor, Director Deutsches Institut für Demenzprävention (DIDP)*

1.C: *Building a 21st Century Global Clinical Trial Infrastructure*  
Luc Truyen, *Vice President, Neuroscience External Affairs & Chair, Global Fight Against Alzheimer’s Disease, Janssen Pharmaceutical*
SESSION 2 - MOBILIZING THE GLOBAL PATIENT COMMUNITY
14:30 - 15:45

Moderated by Gautam Maitra, Head of Regulatory and External Affairs, AC Immune

In recent years a number of initiatives and national and international efforts have been undertaken to address the challenges in the field of dementia. Yet, the speed of the global response is going to be measured by the degree of international consensus, collaboration and shared action - and also the level of engagement of people living with dementia. The purpose of the discussion will be to increase understanding of the strategies and action plans to rally people, communities, countries and regions behind the global fight to stop dementia.

2.A: Living with Dementia
Hilary Doxford, Alzheimer’s Society, Research Network Volunteer; Member, World Dementia Council

2.B: Leveraging the Engagement of the Dementia Community into Research
Marc Wortmann, Executive Director, Alzheimer’s Disease International (ADI)

2.C: A Novel Patient/Caregiver Driven Research Network in Alzheimer’s
Meryl Comer, President, Geoffrey Beene Foundation Alzheimer’s Disease Initiative

2.D: Big Data for Better Outcomes: Public-Private Partnership to Drive Real World Evidence
Frederic de Reydet de Vulpillieres, Director, Global Patient Access, Novartis
Kristin Kahle Wrobleski, Principal Research Scientist, Eli Lilly and Company
SESSION 3 - IMPROVING HOW BIOMARKERS GET TO MARKET
16:15 - 18:00

Moderated by Husseini Manji, Global Head of Neuroscience, Janssen, Chair of the Foundation of National Institute of Health Neuroscience Biomarkers Consortium

Advances in the understanding of progression of dementia at the cellular and molecular levels have spurred new research approaches. New technologies will facilitate diagnosis of the disease and development of drugs for dementia. As the relationship between a class of drugs and a biomarker becomes better understood, there is hope that it will be possible to identify patients most likely to benefit from the drug at increasingly earlier stages of the disease. Early and frequent interaction between industry and regulatory bodies will ensure studies are appropriately designed and biomarker test performance is well characterized.

3.A: Biomarkers: Progress Towards Surrogate Markers for Measures of Drug Effect
Philip Scheltens, Professor, Cognitive Neurology, Director, Department of Neurology and Alzheimer Center, VU University Medical Center

3.B: Improving Diagnosis
Harald Hampel, Professor and AXA Research Fund-UPMC Chair at the Sorbonne Universities, Pierre and Marie Curie University (UPMC), Department of Neurology, Paris, France

3.C: Update on Prevention Studies
Serge Gauthier, Director of the Alzheimer's Disease Research Unit, Medical studies at the Université de Montréal

3.D: Supporting Validation for Regulatory Use: An EU Perspective
Maria Isaac, Senior Scientific Officer, European Medicines Agency

3.E: Drug Development for Alzheimer’s Disease: Lessons Learned from Current Immunotherapy Trials
Roger Nitsch, Professor, University of Zurich

17:15 - 18:00 Q&A

18:00 - 19:00 RECEPTION
DAY TWO - 16 DECEMBER

KEYNOTE
09:00 - 09:30

John C. Reed, Roche, Global Head of Pharma Research and Early Development; Member, Roche Corporate Executive Committee

SESSION 4 - ENSURING ACCESS TO FUTURE THERAPIES AND DIAGNOSTICS
09:30 - 11:50

Moderated by Heiner Sandmeier, Deputy Secretary General, Interpharma

A vital step towards stopping Alzheimer’s disease is to ensure universal access to high-quality healthcare, therapies and diagnostics. This responsibility belongs to all stakeholders. As innovations make it to market, the ability to address the huge unmet needs in Alzheimer’s disease depends on the ability pharmaceutical companies, diagnostic developers, payers and policy makers to agree on the value of treating, caring and supporting those living with the disease.

4.A: Demonstrating the Cost Effectiveness of Treating Dementias: Exploring the Process and Challenges
Anders Wimo, MD, PhD, Adjunct Professor, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet

4.B: How Will Value be Determined: European and US Perspectives on Treatment and Prevention
Louis Jacques, Chief Clinical Officer, ADVI, former Director, Centers for Medicare & Medicaid Services’ Coverage and Analysis Group

Thomas Zeltner, Board Chairman, KPT, former Secretary of the Health of Switzerland Federal Department of Home Affairs FDHA

4.D: Value of Treating Alzheimer’s Disease: Innovators Perspective
Chris Leibman, Vice President, Global Market Access, Biogen

10:20 - 10:50  COFFEE BREAK

4.E: Value of Early Diagnosis Alzheimer’s Disease: Innovators Perspective
Ludger Dinkelborg, Managing Director, Imaging Division, Piramal

4.F: Delivering Innovative Medicines – Is the Required Healthcare Infrastructure in Place?
Phyllis Barkman Ferrell, Global Brand Development and Product Team Leader for Alzheimer’s Disease, Eli Lilly
SESSION 5 - DISCUSSION: THE WAY FORWARD IN ALZHEIMER’S DISEASE AND OTHER DEMENTIAS

11:50 - 12:30

A conversation led by Dirk Pilat, Deputy Director, Science, Technology and Innovation, Organisation for Economic and Co-operation and Development and George Vradenburg, Global CEO Initiative on Alzheimer’s Disease

The purpose of this session is to gain the collective input of the Lausanne II workshop participants and define the actions that can be taken forward and the progress that can be made in 2016.

12:30   CLOSING OF WORKSHOP

Isabella Beretta, Swiss State Secretariat for Education, Research and Innovation
WORKSHOP SPEAKERS AND MODERATORS

PHYLLIS BARKMAN FERRELL
Phyllis Ferrell is V.P. and Global Alzheimer’s Disease Platform Team Leader in Lilly BioMedicines. Phyllis and her team are responsible for the late-stage development and global registration of Solanezumab, Amyvid and AZD3293, including global launches and commercialization. The team is also planning for several other earlier stage assets targeted at treating patients and supporting their caregivers.
Phyllis received a Bachelor of Arts degree in economics and management from DePauw University. She received an MBA in General Management and a certificate in Public Management from the Stanford University Graduate School of Business in 2001.
In 2014, Phyllis was recognized with the Rising Star Award from the Healthcare Businesswomen’s Association. She is a member of the Indiana Chapter of the HBA, on the Board of Directors for the Indiana Chapter of the Alzheimer’s Association, a founding member of Women Against Alzheimer’s, and a wife and mother of two boys.

ISABELLA BERETTA
Isabella Beretta is Scientific Advisor for International Cooperation in Research and Innovation at the Swiss State Secretariat for Education, Research and Innovation SERI. She is responsible for the development of research policy and the elaboration of Swiss positions in the context of international research organisations and programmes. Furthermore, she acts as head of the Swiss delegation of several international research institutions. Her domains of work include interdisciplinary research in the life sciences and research infrastructures, biotechnology, bioeconomy, molecular biology, marine sciences, neuroinformatics, risk governance, innovative medicines and clinical trials. She has been involved in scientific collaboration for many years, such as Secretary General of the European Molecular Biology Conference (EMBC) 2007-2008, Chair of the European Molecular Biology Laboratory (EMBL) Finance Committee, Vice-President of the Board of the Human Frontier Science Program Organisation (HFSPO) and Chair of its Finance Committee, Vice-Chair of the European network of national programmes in clinical trials of EDCTP, Chair of the OECD Working Party on Biotechnology in 2014. Isabella Beretta studied biochemistry, cell biology and organic chemistry at ETH, she earned her PhD at the Institute of Biotechnology of ETH.
**CLAUS BOLTE**

Claus Bolte MD, MBA trained as a General and Transplant Surgeon in Europe and North America, held clinical and academic positions for 10 years, subsequently worked for the research-based pharmaceutical, biotech and medical device industry. Since 2012 he is Division Head of Clinical Review (Marketing Authorization) at Swissmedic in Bern, Switzerland. Claus also teaches at ETH Zürich, previously at the University of Erlangen-Nuremberg. International activities include ICH, ACSS (Australia, Canada, Singapore, Switzerland) Regulatory Consortium, as well as the Integrated Development/Regulatory Research Group.

**MERYL COMER**

Meryl Comer is president and CEO of the Geoffrey Beene Foundation Alzheimer’s Initiative, which promotes early diagnosis, virtual innovation challenges, mhealth technologies and national public service campaigns like Geoffrey Beene’s Rock Stars of Science™. A co-founder of WomenAgainstAlzheimer’s, Comer is the recipient of the 2015 Lauder Alzheimer’s Drug Discovery Fund “Great Ladies” Award, 2014 Wertheim Global Medical Leadership Award, 2007 Proxmire Award and 2005 Shriver Profiles in Dignity Award. In 2012, she led the formation of the 21st Century BrainTrust® (21CBT), a non-profit partnership to advance mobile health technologies and brain health.

Comer has used her media expertise as an Emmy award-winning reporter, veteran TV producer/business talk show host, and 20 years as a caregiver to co-launch a virtual Health-eBrainStudy that looks at the impact of caregiving on caregivers. She is also co-principal investigator for the PCORI Alzheimer’s Patient/Caregiver Research Network in partnership with the Mayo Clinic, UCSF’s Brain Health Registry, and USAgainstAlzheimer’s Networks.

Comer has been the subject of primetime news stories by ABC’s Nightline and the PBS NewsHour with Jim Lehrer.


**FREDERIC DE REYDET DE VULPILLIERES**

Frederic has 18 years’ experience working in healthcare industry with focus on payer and patient access. Frederic is responsible for Global Patient Access for Neuroscience at Novartis Global Headquarters in Basel, Switzerland. Frederic joined Novartis 5 years ago from F.Hoffmann-La Roche AG where he was responsible for the development and execution of Global payer and patient access strategies in oncology. Prior to this experience Frederic was UK based working for IMS Consulting (formerly Cambridge Pharma Consultancy).

Frederic holds a Master (MSc) in Economic Evaluation in Health Care (with distinction) from London City University as well as BA Business Administration from London Guildhall University.
LUDGER DINKELBORG
Dr. Ludger Dinkelborg serves as the CEO of Piramal Imaging, an established leader in the field, which was created through the acquisition of the targeted molecular imaging portfolio of Bayer Pharma AG. The portfolio addresses indications in neurology, oncology and cardiology allowing earlier and more precise diagnosis as well as monitoring therapeutic outcome. The lead product, NeuraCeq™, is approved for the detection of amyloid beta in patients evaluated for Alzheimer’s disease. Before co-founding Piramal Imaging, Dr. Dinkelborg served as Head of Diagnostic Imaging Research and Head of Molecular Imaging at Bayer HealthCare. He brings more than 20 years of R&D experience in the pharmaceutical industry. He received his PhD in biology at Heinrich-Heine-University, Duesseldorf, Germany and stayed as guest researcher at the Max-Planck-Institute for Molecular Physiology in Dortmund. He became a fellow of the Konrad-Adenauer-Foundation, attended the Cranfield Schering University course for managers, and the Stanford Executive Program at Stanford School of Business.

HILARY DOXFORD
In December 2012, at the age of 53 Hilary was diagnosed with early onset Alzheimer’s Disease. She is an ambassador for the Alzheimer’s Society in England and a member of their research network. She is also the representative for England on Alzheimer Europe’s, European Working Group of People with Dementia and last October was invited to speak at the World Dementia Council meeting in London following which in January this year she was offered a seat on the Council as the voice of a person with dementia.
She has a background in research and has been a business manager for over thirty years. She is still working and intends to continue working for as long as possible to show that people with dementia can still make a valuable contribution to their organisation and society.

TANIA DUSSEY-CAVASSINI
Tania Dussey-Cavassini combines experience in global health, management consulting, executive education, diplomacy and law enforcement. Since 2013, she is Ambassador for Global Health and Vice-Director General of the Swiss Federal Office of Public Health, in charge of International Affairs. Between 2006 and 2012, Tania was Director at IMD, ranked #1 worldwide in Executive Education. Since 2010, she is also an adviser to the United Nations Institute for Training and Research (UNITAR). Tania has held diplomatic assignments in Paris, Bern, Moscow and Geneva. She started her career as a lawyer in 1991 working in the realm of international criminal matters and extradition proceedings. Tania is a Harvard Fellow. She was educated in management at IMD, in law at the University of Lausanne, and music at the University of Music Lausanne, Switzerland.
SERGE GAUTHIER
Medical studies at Université de Montréal, Neurology training at McGill University, Research Fellowship at Prof. Theodore L. Sourkes laboratory, Allen Memorial Institute, Montreal. Clinical investigator and staff neurologist at the Montreal Neurological Hospital and Institute (1976-1986), Director of the McGill Centre for Studies in Aging (1886-1996), Senior Scientist of the CIHR-Rx&D program (1997-2007). Currently Professor in the Departments of Neurology & Neurosurgery, Psychiatry, Medicine, at McGill University, and Director of the Alzheimer Disease and Related Disorders Research Unit of the McGill Center for Studies in Aging, Douglas Hospital. Recipient of the Order of Canada in December 2014. Contributions to research include development of design and outcomes for randomized clinical trials in order to establish the safety and efficacy of treatments against Alzheimer’s disease. Special interests in consensus approach to the diagnosis and management of Alzheimer’s disease in its different stages, the ethics of research involving persons with dementia, and primary prevention strategies against cognitive decline and dementia.

HARALD HAMPEL
Harald Hampel is Professor and AXA Research Fund-UPMC Chair at the Sorbonne Universities, Pierre and Marie Curie University (UPMC), Department of Neurology, Paris, France and will be standing in for Bruno Dubois in Session 3. He is Scientific Director of the Institute for Memory and Alzheimer’s disease. Dr. Hampel obtained his MD and PhD at the University of Munich and holds an MSc from Cologne University, and an MA from Trinity College, University of Dublin. Post-doctoral fellowship at the NIH/NIA Laboratory of Neurosciences, Bethesda, Md. He has authored more than 570 peer-reviewed papers, 80 bookchapters and 8 books. His interests embrace the neurodegenerative diseases, biological markers, neuroimaging, genetics, clinical trials and drug development. For his scientific work on Alzheimer’s disease he received numerous awards. He has been a reviewer for leading scientific journals and funding agencies in the US, Canada and Europe and is senior associate editor of the journal Alzheimer’s & Dementia of the Alzheimer’s Association.

TOBIAS HARTMANN
Tobias Hartmann is chair for Experimental Neurology and scientific director of the Deutsches Institut für Demenzprävention at medical faculty of the Saarland University in Germany. Hartmann coordinates the European LipiDiDiet project which addresses the Impact of Nutritional Lipids on Neuronal and Cognitive Performance in Aging and especially in prodromal Alzheimer’s disease. Further programs coordinated by Hartmann include the program dementia prevention (PDP) in Luxembourg, which aims to translate and to integrate the scientific progress in this area into the national health care system. Molecular studies include the identification of physiological and patho-physiological metabolic and lipidic pathways in AD and nutritional approaches in AD, including design and analysis of food in respect to preventive or risk management potential. Identification of the molecular, development of novel biomarkers either in food or humans in respect to its risk/preventive potential for Alzheimer’s disease.
MARIA ISAAC
Dr Maria Isaac is a Senior Scientific Officer at the European Medicines Agency (EMA) for the past ten years. During this time, her responsibilities have included conducting and overseeing scientific advice, protocol assistance, parallel HTA/SA/PA and qualification of novel methodologies, for a variety of therapeutic areas CNS, rheumatology, endocrinology, cancer, cardiology and orphan diseases. She has over 25 years’ international experience in academic, clinical and regulatory fields.
A UK citizen and native of Spain, Dr Isaac qualified in medicine at the University of the Basque Country and obtained a Master’s degree from Temple University, Philadelphia (USA). She is qualified as an Adult General Psychiatrist, as a General Practitioner, Pharmaceutical Medicine Physician (UK & Spain).
She has wide experience in molecular biology research as Research Fellow at University of Pennsylvania (USA) and in the Institute of Psychiatry (University of London, UK), as well as in clinical research. Her career has focused on novel and innovative pharmacological treatment, biomarkers, clinical outcomes and clinical management of mental illness.
Dr Isaac obtained her PhD in the psychopharmacology of depression at the University of London (Guy's Hospital 1998). She was a Consultant Psychiatrist & Co-Director of Psychopharmacology Evaluation Unit at the South London & Maudsley NHS Trust in London, and Hon Senior Lecturer at the Institute of Psychiatry, UK. She is Vice-Chair of the Royal College of Psychiatrist's Psychopharmacology Special Committee (UK).

LOUIS B. JACQUES
Louis Jacques, M.D. is Chief Clinical Officer and a Senior Vice President at ADVI, where he is also a partner. ADVI is a health care advisory services firm with offices in Washington DC, Austin, and San Francisco. He also serves on several institutional boards. Before joining ADVI in 2014, Dr. Jacques was the Director of the Coverage and Analysis Group (CAG) in the Centers for Medicare & Medicaid Services (CMS) from 2009 - 2014, where he managed Medicare fee for service coverage policy development on technologies as diverse as molecular diagnostic testing, implanted cardiac devices, advanced imaging, chemotherapeutics, wound care, and screening and preventive services. From 2004 – 2009 he was a division director within CAG.
Before joining CMS in 2003, he served as the Associate Dean for Curriculum at Georgetown University School of Medicine; where he also saw patients at the Lombardi Cancer Center in his practice of hospice and palliative medicine.
YOSHIKO KOMURO
Dr. Yoshiko Komuro serves as a deputy review director in office of new drugs II in Pharmaceuticals and Medical Devices Agency (PMDA). She is currently engaged in a review of drugs for Alzheimer’s disease and Parkinson’s disease, etc. She joined PMDA in 2006 and had been working as a reviewer of neurology and psychiatry drugs for 6 years. In April of 2012, she started to work in the University of Tokyo Hospital as an assistant professor and worked in Translational Research (TR) Center to support TR project. Because of the expiration of her term of office, she returned to PMDA in April of 2014. She received her Ph.D from Graduate School of Pharmaceutical science, the University of Tokyo in 2006. Her specialized field was molecular biology.

CHRIS LEIBMAN
Chris Leibman is Vice President Health Economics and Outcomes Research, Global Market Access at Biogen, where he leads the value evidence planning and execution of global health economics, outcomes research and comparative effectiveness evidence generation strategies across the Biogen portfolio. Prior to joining Biogen in 2014, Chris served as head of Global Health Economics, Market Access and Policy: Neuroscience at Janssen Pharmaceuticals, where he led a team responsible for the generation of health economics/outcomes evidence and market access strategies across the Neuroscience franchise. Prior to this, first with Élan Pharmaceuticals and then with Janssen AI following their program acquisition, Chris led the value demonstration and launch readiness activities across the Alzheimer Immunotherapy Program in partnership with Pfizer. Chris brings a number of diverse experiences in Alzheimer’s and dementia biopharmaceutical development, commercialization, and working across multi-company alliances.

RAJ LONG
Raj Long is a senior pharma executive with over 20 years of global development experience in the pharmaceutical industry including GEHC, Merck, Bristol-Myers Squibb and Novartis where recent roles include Vice President – Regulatory International. She is currently a Senior Advisor at the Bill & Melinda Gates Foundation (BMGF). She is a member of the World Dementia Council and is the lead for the G7 Integrated Development effort to find an accelerated development pathway for Dementia. She is also appointed to the Innovative Medicines and Medtech Review Advisory Group, appointed by the Parliament Undersecretary for Health (Sir John Freeman). Additionally, Raj is also an Expert Reviewer in the EC Innovative Medicines Initiative (IMI) 2 Joint Undertaking by the European Commission and Private Sector. She has held various positions in industry expert groups including ICH Expert and EFPIA Lead. Raj has an outstanding track record in shaping successful regulatory strategy in drug development that enables catalytic accelerated market access globally.
GAUTAM MAITRA
Sweden trained chemist and regulatory affairs professional with over 14 years’ experience in two of Forbes top rank pharmaceutical companies, namely Roche and Novartis. At Novartis he was in charge of the regulatory support for both marketed and early development products.
Since 2007 he has been the Head of Regulatory and External Affairs at AC Immune reporting to the Chief Executive Officer. Here he manages Alzheimer’s disease Clinical Trial Applications (CTA/IND), major Pre-IND meetings and interactions with the FDA, EMA and other Agencies, manages the Regulatory Affairs and Quality Assurance teams. He is a regular member of the Project Core Teams where he plans and presents global regulatory strategies for Alzheimer’s drug development besides giving regulatory input and liaising with Health Authorities when necessary.
Before joining AC Immune SA, he served in a Lyon-based biotech company, OPi/EUSA, where he was the Director of Chemistry, Manufacturing and Controls. Gautam also served as the European Director of one of the world’s biggest pharmaceutical professionals associations (Parenteral Drug Association) with over 10,000 members worldwide from the pharmaceutical and biopharmaceutical industries, health authorities and academia. During that period he developed strong relationships with major health authorities like the FDA, EMA, BfArM, ANSM, MPA, MHRA, Swissmedic etc. and also developed relationships with bodies like the ICH, EFPIA, WHO, PIC/S. He was an invited observer to the annual USP European Stakeholder Forums. He has also been a member of the Bio-Manufacturing Working Group of the EFPIA/EBE in Brussels and a member of the PDA Task Force for early Phase Clinical Trials material.

HUSSEINI K. MANJI
Husseini K. Manji, MD, FRCPC is Global Therapeutic Head for Neuroscience at Janssen Research & Development, LLC, a division of Johnson & Johnson. Previously, he was Chief, Laboratory of Molecular Pathophysiology & Experimental Therapeutics, NIH, and Director of the NIH Mood and Anxiety Disorders Program. Dr. Manji received his B.S. and M.D. from the University of British Columbia. He completed fellowship training at the NIMH and completed additional training in cellular and molecular biology. His research has focused on investigation of disease- and treatment-induced changes in gene and protein networks that regulate synaptic and neural plasticity. His work has led to investigation of novel therapeutics for patients with refractory neuropsychiatric illnesses. Dr. Manji has also been involved in medical and postgraduate neuroscience education and has published extensively on the molecular and cellular neurobiology of neuropsychiatric disorders and the development of novel therapeutics. Dr. Manji has received numerous distinguished scientific and academic awards, including the NIMH Director’s Career Award for Significant Scientific Achievement, and was inducted in to the U.S. Institute of Medicine of the National Academies in 2008. He has served as Chair of the American College of Neuropsychopharmacology, is a Counselor to the Society of Biological Psychiatry and serves on a variety of editorial boards of scholarly journals. He holds voluntary leadership positions in many organizations devoted to advancement of neuroscience and advocacy for people with neuropsychiatric illnesses. He has been a member of the Howard Hughes Medical Institute and NIH Research Scholars Program Advisory Committee.
ROGER M. NITSCH

Roger M. Nitsch is a Professor of Molecular Psychiatry at the University of Zurich. He is a founder and the President of Neurimmune, a Swiss biotech company focusing on the development of antibody-based treatments for neurodegenerative diseases. Neurimmune’s most advanced drug Aducanumab, a human monoclonal antibody for the treatment of Alzheimer’s disease is developed in collaboration with Biogen in phase 3 clinical trials.

A neuroscientist with a background in medicine, Roger M. Nitsch is recognized as a pioneer of disease-modifying therapeutic approaches for neurodegenerative diseases with more than 25 years of experience in Alzheimer’s disease research. He directs the Division of Psychiatry Research at the University of Zurich, Switzerland. He serves as Editor-in-Chief for Neurodegenerative Disease, and is an Executive Organizer of the International Conferences on Alzheimer’s and Parkinson’s Diseases, the AD/PD meetings. Prior to his position at the University of Zurich, Roger M. Nitsch held research positions at M.I.T., MGH / Harvard Medical School, Boston, and the Center for Molecular Neurobiology at University of Hamburg, Germany. He was a fellow at the Max-Planck-Institute for Medical Research in Heidelberg, Germany, and received an M.D. from University of Heidelberg Medical School.

Roger Nitsch is an elected member of the German Academy of Sciences Leopoldina, he is the recipient of the Potamkin Award for Research in Pick’s, Alzheimer’s and Related Diseases, as well as the President’s Award of the American Federation for Aging Research.

ANDREA PFEIFER

Prof. Dr. Andrea Pfeifer is CEO of AC Immune, a Biotech company with three products in clinical development for Alzheimer’s disease, which she co-founded in 2003 (www.acimmune.com).

As former Head of Nestlé’s Global Research in Lausanne, Switzerland, she has more than 25 years of senior management experience leading the development of the first Functional Food and Cosmeceutical Products. During this time, she also co-founded the Nestlé Venture Capital Fund, a EUR 100 Mio. Life Sciences corporate venture fund. She is Chairwoman of BioMedInvest AG and AB2Bio, serves on the board of Symrise AG and holds a professorship from the UNIL and EPFL, Lausanne.

Prof. Pfeifer is a registered Pharmacist and Toxicologist and author of more than 200 papers and abstracts in leading scientific journals. She was recognized as Technology Pioneer by the WEF and Swiss Entrepreneur of the Year by Ernst&Young in 2009. Other recognitions include the BioAlps prize 2013, the election as one of the top 10 women in biotech from Fierce Biotech and one of the 300 most influential personalities in Switzerland.
DIRK PILAT
Mr. Dirk Pilat, a Dutch national, is Deputy Director of the OECD Directorate for Science, Technology and Innovation. As Deputy Director, he supports the Director of STI in pursuing the Directorate’s programme of work and contributing to the achievement of the strategic goals of the Organisation as defined by the OECD Secretary-General.
He joined the OECD in February 1994 and has worked on many policy issues since then, including the OECD Innovation Strategy and OECD Green Growth Strategy, how to draw greater benefits from information technology for economic growth, how to strengthen growth performance in OECD economies (the OECD Growth Project), how to strengthen the performance of the services sector, as well as work on climate change, labour markets, product market regulation, productivity and entrepreneurship. He was Head of the Science and Technology Policy Division from 2006 to January 2009, with responsibility for the OECD’s Committee for Scientific and Technological Policy, and Head of the Structural Policy Division, with responsibility for the OECD’s Committee on Industry, Innovation and Entrepreneurship, from February 2009 to December 2012.
Before joining the OECD, Mr. Pilat was a researcher at the University of Groningen, in the Netherlands, where he also earned his PhD in Economics. He has published extensively in a range of economics journals, with a strong focus on international comparisons of growth and productivity performance.

JOHN C. REED
Dr. John Reed is global head of the Roche Group’s Pharmaceutical Research & Early Development (pRED) unit and member of the Corporate Executive Committee. He directs R&D activities from discovery of a promising target through to Phase 2 proof of concept clinical trials for all Roche’s therapeutic areas of focus. These currently include oncology, neuroscience, infectious diseases, immunology, ophthalmology and rare diseases.
Prior to joining Roche in 2013, Dr. Reed served as CEO of one of the largest non-profit biomedical research institutes in the United States, and ran a laboratory that generated more than 800 research publications, over 90 patents and was awarded hundreds of research grants. He also served on multiple editorial boards of biomedical research journals and on various advisory committees and boards for biopharmaceutical and biotechnology companies as well as public and private non-profit biomedical research organizations. Dr. Reed is also an Adjunct Professor at ETH Zurich and a Fellow of the American Association for the Advancement of Science.
HEINER SANDMEIER
Dr. Heiner Sandmeier is Deputy General Secretary of Interpharma, the association of the Swiss Pharmaceutical Research Companies. He has more than 17 years of experience in the fields of pharmaceutical, health, and science policy. Before joining Interpharma in 1997, he was a research fellow in molecular biology and microbiology at the University of Basel. He graduated in molecular biology and received a PhD degree in microbiology and a master’s degree in Public Health from the Universities of Basel, Bern, and Zürich.

SHEKHAR SAXENA
Dr. Saxena is a psychiatrist by training, working at World Health Organization since 1998 and as the Director of the Department of Mental Health and Substance Abuse since 2010. His responsibilities include providing advice and technical assistance to ministries of health on prevention and management of mental, developmental, neurological and substance use disorders and suicide prevention. His work also involves establishing partnerships with academic centres and civil society organizations and global advocacy for mental health, neurology and substance use issues. Dr Saxena is leading WHO’s work to implement the Comprehensive Mental Health Action Plan adopted by the World Health Assembly in May 2013 and scaling up care for priority mental, neurological and substance use disorders. He is also responsible for taking forward WHO’s commitments on dementia, including the establishment of WHO’s Global Dementia Observatory.

PHILIP SCHELTENS
Dr Philip Scheltens studied at the VU University, Amsterdam, The Netherlands, gaining his MD in 1984, and PhD (Magnetic Resonance Imaging in Alzheimer’s disease) in 1993.
Dr Scheltens is Professor of Cognitive Neurology and Director of the Alzheimer Center at the VU University Medical Center in Amsterdam, as well as Honorary Professor of Neurology at University College London. From 2011-2015 he has been the scientific director of the Dutch Pearlstring Institute (PSI). In 2012 he initiated the Dutch “Deltaplan Dementie” and was appointed as vice-chair of the board in 2013. He is founder of, and has directed since 2000 the VUmc Alzheimer Center, which under his directorship produced to date over 54 PhD theses.
He has authored more than 695 peer reviewed papers and more than 50 book chapters and co-edited several textbooks. In 2015 his first Dutch book entitled “het Alzheimer Mysterie” was published (Arbeiderspers), which entered the bestseller list in 2 weeks.
He was elected member of the Royal Academy of Arts and Sciences in 2011 and was elected as member of the board in 2015.
PETER SCHINTLMEISTER

Peter Schintlmeister completed his studies at the Technical University of Graz as a Chemical Engineer with emphasis on Industrial Biotechnology. After positions in industry and non-profit-organisations he joined the Federal Ministry of Economics and Labour (now the Federal Ministry of Science, Research and Economy) in 2002, where he since is in charge of the area of Life Sciences and Biotechnology.

His main duty lies in improving policy framework conditions for start-ups and spin-offs in Life Sciences through - financial and non-financial - governmental support measures and in strategically fostering cooperation between academia and industry through measures of technology policy.

Peter Schintlmeister currently holds chairmanships of the OECD’s Working Party on Bio-, Nano- and Converging Technologies (BNCT) and the European Commission’s Expert Group for Bio-Based Products. He also is a member of the European Commission’s Bioeconomy Panel.

In 2013 Peter Schintlmeister was temporarily attached to the Austrian Embassy in Beijing, China, where he served as deputy head of the Science and Technology Section.

EMMA SPREEKMEESTER

Emma Spreekmeester is the manager of the Central Nervous System Division 1 (CNSD1) at the Therapeutic Products Directorate (TPD) of Health Canada. She joined Health Canada in 2005 and worked as a drug reviewer until 2014, when she assumed the manager position in the CNS Division. During her career at Health Canada, Emma has participated actively on several internal regulatory committees, addressing topics such as Women in Clinical Trials and Orphan Drugs. She is currently part of the organising committee to establish an Alzheimer’s Disease Symposium at Health Canada and is keenly interested in this emerging field of drug development. Emma completed both her Ph.D. in Neuroscience and her M.Sc in Psychiatry at McGill University, in Montreal, Quebec.
LUC TRUYEN
Luc was trained as a neurologist in Belgium and the Netherlands with in addition a PhD in Medical Sciences from the University of Antwerp. After a career in academia with special interest in multiple sclerosis, stroke and neuro-degenerative disease he joined Janssen Research Foundation (JNJ) in 1998. He was part of the team that developed Reminyl/Razadyne™ for the symptomatic treatment of AD in early 2000’s. After that he has had roles of increasing responsibilities and scope within JNJ. From 2011-2013 Luc was Head of R&D and CMO of Janssen Alzheimer Immunotherapy LLC. In recognition of the increasing sense of urgency and required focus on Alzheimer’s Disease Luc was named VP Neuroscience External Affairs and Chair, Johnson&Johnson, Global Fight against Alzheimer’s Disease in April 2014. This to coordinate all efforts for JNJ in the external environment related to AD (IMI, GAP, G7, etc). He is EFPIA co-lead for IMI-EPAD and IMI 2 Neurodegeneration SGG, serves on the oversight committee of the Dementia Platform UK, is a member of the Scientific Advisory Board of the Dementia Discovery Fund and leads the industry advisory committee of the Global Alzheimer Platform.

GEORGE VRADENBURG
George Vradenburg is Chairman of USAgainstAlzheimer’s, which he co-founded in October 2010. George was named by U.S. Health and Human Services Secretary Kathleen Sebelius to serve on the Advisory Council on Research, Care, and Services established by the National Alzheimer’s Project Act and has testified before Congress about the global Alzheimer’s pandemic. He is a member of the World Dementia Council.

George and USAgainstAlzheimer’s co-convene both the Leaders Engaged on Alzheimer’s Disease (LEAD) Coalition and the Global CEO Initiative on Alzheimer’s Disease. He and his wife, Trish, have long been dedicated members of Washington’s civic and philanthropic community. George is Chairman of the Board of The Phillips Collection and a member of the Council on Foreign Relations and The Economic Club of Washington. He has served in senior executive and legal positions at CBS, FOX and AOL/Time Warner.
ANDERS WIMO
Anders Wimo’s research areas are geriatric health economy and epidemiology. He participates in the steering committees of the population project Swedish National study on Aging and Care and the Swedish dementia quality assurance register (SveDem). Professor Wimo has written several reports for the National Board of Health and Welfare and he was one of the experts of the Swedish Dementia national guidelines in 2010 as well as its ongoing update. He is also a member of the European Alzheimer Disease Consortium (EADC) and is an expert for Alzheimer Europe. He co-authored Alzheimer Disease International’s Word Alzheimer Report 2010 (the global economic burden of dementia) and its update in 2015. He co-authored WHO’s report Dementia – a public health priority from 2012 and he participated in WHO’s ministerial conference in Geneva in 2015. He has participated in several EU projects. He has written more than 280 papers, reviews, book chapters and reports.

MARC WORTMANN
Marc Wortmann is Executive Director of Alzheimer’s Disease International (ADI). Marc studied Law and Art in the city of Utrecht in the Netherlands and was an entrepreneur in retail for 15 years. During this time Marc was a member of the Parliament of the Province of Utrecht and worked closely with various charities and voluntary organisations. He became Executive Director of Alzheimer Nederland in 2000. From 2002 to 2005 he chaired the Dutch Fundraising Association and was Vice-President of the European Fundraising Association from 2004 to 2007. Marc joined ADI at the end of 2006 and is responsible for external contacts, public policy towards WHO and UN, the annual international conference and fundraising. He is a speaker at multiple events and conferences on these topics and has published a number of articles and papers on dementia awareness and public policy.

KRISTIN WROBLESKI
Kristin Kahle Wrobleski, Ph.D. is the Research Team Leader for Alzheimer’s and Neurodegenerative Diseases in the Global Patient Outcomes and Real World Evidence group at Eli Lilly and Company. She joined Lilly to lead payer-focused research and strategy of Lilly’s Alzheimer’s portfolio. Dr. Wrobleski has collaborated extensively with colleagues in academia and industry on a variety of research projects and initiatives to advance the science of conducting value-based assessments.

Dr. Wrobleski is also a licensed psychologist and serves on the clinical faculty of the Neuropsychology Clinic in the Indiana University School of Medicine Department of Psychiatry. She completed a doctorate in clinical psychology at the University of Kansas where she was a National Institutes on Aging Predoctoral Fellow in Communication and Aging. She completed her postdoctoral studies at the University of California, Irvine, Institute for Brain Aging and Dementia.
THOMAS ZELTNER

Thomas Zeltner, a doctor, lawyer, and for 19 years the Secretary of Health of Switzerland and Director-General of the Swiss National Health Authority, has a long history as an innovative and progressive leader in public health. Currently he is chairman of the KPT insurance company, repeatedly ranked as the most innovative health insurance plan in Switzerland. He is also a member of the board of the Swiss Academies of Arts and Sciences. Since 1992, he has been Professor of Public Health at the University of Berne and is a Visiting Scientist at the Harvard School of Public Health (Boston). He chairs the Board of the Global Health Programme at the Graduate Institute in Geneva.

He serves as Patron for the Synapsis Foundation for Alzheimer Research, Switzerland (www.synapsisfoundation.ch/) and as Chairman of the Advisory Board of Give To Cure Alzheimer, USA (www.givetocure.org/).

Most recently he also served as Special Envoy of the World Health Organization (2012-14). In this capacity he advised the Director General of WHO Margaret Chan in critical areas of the ongoing reform of this UN agency (how to cooperate with NGO’s, academia and the private sector without compromising WHO’s integrity; how to better align WHO’s priorities with the monies available to finance them).

Thomas Zeltner is born in Bern (Switzerland). He graduated with a MD and a Master’s degree in Law from the University of Bern. He is a 2010 Fellow of the Harvard Advanced Leadership Initiative and Doctor of Laws (honoris causa) of the University of Neuchatel.
ABOUT OUR ORGANIZATIONS

The State Secretariat for Education, Research and Innovation SERI is the federal government’s specialised agency for national and international matters concerning education, research and innovation policy.

The mission of the Organisation for Economic Co-operation and Development (OECD) is to promote policies that will improve the economic and social well-being of people around the world.

The Global CEO Initiative on Alzheimer’s Disease (CEOi) is an organization of private-sector leaders providing business leadership in the fight against Alzheimer’s. The CEOi partners with leaders from all sectors to transform the disease from a social, health, and economic crisis into an opportunity for healthy aging through innovation in research and care. In this era of aging populations, solving the global challenge of Alzheimer’s will take visionary, coordinated, goal-oriented leadership.

Alzheimer’s Disease International (ADI) believes that the key to winning the fight against dementia lies in a unique combination of Global Solutions and local knowledge. As such, it works locally, by empowering Alzheimer associations to promote and offer care and support for people with dementia and their careers, while working globally to focus attention on dementia.

THANK YOU TO OUR SPONSORS